Search research articles
Contact Us
Filters
Showing results (71-80 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Tumor-informed ctDNA assay to predict outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with PD-1 inhibitor
Natasha Honoré, George Laliotis, Vasily N Aushev, et al.
Frontiers in Oncology
|
October 6, 2023
Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: a population-based study of temporal trends
Hanna M Peacock, Cindy De Gendt, Geert Silversmit, et al.
Annals of Surgical Oncology
|
July 26, 2013
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery
Patrice Forget, Jean-Pascal Machiels, Pierre G Coulie, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I Pai, Sandrine Faivre, Lisa Licitra, et al.
Targeted Oncology
|
February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
James J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
BJU International
|
January 19, 2016
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront, Sylvie Rottey, Bertrand Filleul, et al.
BMC Cancer
|
November 25, 2010
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
Laetitia Gerlier, Mark Lamotte, Ahmad Awada, et al.
Oncology
|
October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)
Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
Molecular Cancer
|
August 31, 2013
Cancer risk in immune-mediated inflammatory diseases (IMID)
Rudi Beyaert, Laurent Beaugerie, Gert Van Assche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts
Lionel Mignion, Stefania Acciardo, Florian Gourgue, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Tumor-informed ctDNA assay to predict outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with PD-1 inhibitor
Natasha Honoré, George Laliotis, Vasily N Aushev, et al.
Frontiers in Oncology
|
October 6, 2023
Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: a population-based study of temporal trends
Hanna M Peacock, Cindy De Gendt, Geert Silversmit, et al.
Annals of Surgical Oncology
|
July 26, 2013
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery
Patrice Forget, Jean-Pascal Machiels, Pierre G Coulie, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I Pai, Sandrine Faivre, Lisa Licitra, et al.
Targeted Oncology
|
February 14, 2023
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
James J Harding, Christiane Jungels, Jean-Pascal Machiels, et al.
BJU International
|
January 19, 2016
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront, Sylvie Rottey, Bertrand Filleul, et al.
BMC Cancer
|
November 25, 2010
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
Laetitia Gerlier, Mark Lamotte, Ahmad Awada, et al.
Oncology
|
October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)
Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
Molecular Cancer
|
August 31, 2013
Cancer risk in immune-mediated inflammatory diseases (IMID)
Rudi Beyaert, Laurent Beaugerie, Gert Van Assche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts
Lionel Mignion, Stefania Acciardo, Florian Gourgue, et al.
Page
of 17